Back to Search
DR. OMAR ETON M.D.
M.D.
Hematology & Oncology Physician
NPI: 1275736050IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
230372(MA)
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
166561(NY)56793(CT)230372(MA)
Medical Oncology Physician
Internal Medicine — Medical Oncology
Code: 207RX0202X
116561(NY)G7403(TX)
Education
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
Class of 1983
Research & Publications (19)
A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence.
PMID 19430405·Melanoma Res·2009
3-trial
A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer.
PMID 19633475·J Thorac Oncol·2009
3-trial
Phase II trial of imatinib mesylate in patients with metastatic melanoma.
PMID 18728664·Br J Cancer·2008
3-trial
Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment.
PMID 18626307·Melanoma Res·2008
3-trial
Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.
PMID 16565971·Cancer·2006
3-trial
Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec).
PMID 16630177·J Cutan Pathol·2006
8-other
Chemotherapy, cytokines, and biochemotherapy for melanoma.
PMID 16110637·Cancer Chemother Biol Response Modif·2005
6-review
Biochemotherapy in patients with metastatic anorectal mucosal melanoma.
PMID 15042682·Cancer·2004
8-other
Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.
PMID 15009722·J Invest Dermatol·2004
7-preclinical
Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma.
PMID 15091196·Melanoma Res·2004
3-trial
Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma.
PMID 15274073·Cancer·2004
4-observational
Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array.
PMID 14507401·J Cutan Pathol·2003
4-observational
Phase II evaluation of temozolomide in metastatic choroidal melanoma.
PMID 12777987·Melanoma Res·2003
3-trial
Phase II trial of 9-nitrocamptothecin (RFS 2000) for patients with metastatic cutaneous or uveal melanoma.
PMID 11901310·Anticancer Drugs·2002
3-trial
Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma.
PMID 12115326·Cancer·2002
3-trial
Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.
PMID 11956264·J Clin Oncol·2002
3-trial
A phase II study of "decrescendo" interleukin-2 plus interferon-alpha-2a in patients with progressive metastatic melanoma after chemotherapy.
PMID 10738230·Cancer·2000
3-trial
Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy.
PMID 11051235·Clin Cancer Res·2000
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 6 locations total
- Address
- 830 HARRISON AVE, MOAKLEY ,3RD FOOR
BOSTON, MA 02118 - Phone
- (617) 638-6428
Locations (6)
Practice Location
830 HARRISON AVE, BOSTON, MA
(617) 638-6428
Practice Location
5920 Saratoga Blvd Ste 395, Corpus Christi, TX
(361) 737-0600
Practice Location
1415 Santa Fe St Ste C, Corpus Christi, TX
(361) 737-0600
SAINT JOHNS EPISCOPAL HOSPITAL
327 BEACH 19TH ST, FAR ROCKAWAY, NY
(718) 869-7000
Practice Location
85 Retreat Avenue, Hartford, CT
(860) 972-3790
CHRISTUS HEALTH ARK-LA-TEX
2602 SAINT MICHAEL DR STE 202, TEXARKANA, TX
(903) 614-5480
Quick Facts
- NPI
- 1275736050
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 6
- Locations
- 6
- Years in Practice
- 43
- Publications
- 19
Are you this provider?
Claim Your Profile